公开(公告)号：US20180030078A1

公开(公告)日：2018-02-01

申请号：US15552587

申请日：2016-02-19

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier SCHERRER ,  Aude GARCEL ,  Noelie CAMPOS ,  Jamal TAZI ,  Audrey VAUTRIN ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Pauline FORNARELLI

IPC分类号： C07H17/02

CPC分类号： C07H17/02 ,  C07D405/12

摘要： The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.

公开(公告)号：US20180031557A1

公开(公告)日：2018-02-01

申请号：US15552660

申请日：2016-02-19

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier SCHERRER ,  Aude GARCEL ,  Noelie CAMPOS ,  Jamal TAZI ,  Audrey VAUTRIN ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Pauline FORNARELLI

IPC分类号： G01N33/569

CPC分类号： G01N33/56983 ,  G01N2333/16 ,  G01N2469/10 ,  G01N2500/02 ,  G01N2500/10

摘要： The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).

公开(公告)号：US20180028522A1

公开(公告)日：2018-02-01

申请号：US15552921

申请日：2016-02-19

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier SCHERRER ,  Aude GARCEL ,  Noelie CAMPOS ,  Jamal TAZI ,  Audrey VAUTRIN ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Pauline FORNARELLI

IPC分类号： A61K31/47 ,  A61K31/706

摘要： The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.